SS 36 - Predicting Benefit and Toxicity: Biomarkers in Prostate Radiotherapy

Presentations

• 03:45pm - 03:55pm ET

  Germline Biomarker for Late Genitourinary Adverse Events after Radiotherapy for Prostate Cancer: Validation in Multiple Prospective Trials

  Speaker: Amar Kishan, MD - UCLA, Culver City
• 03:55pm - 04:05pm ET

  Genomic Stratification of Benefit from Short-Term Androgen Deprivation with Dose-Escalated Radiotherapy in Intermediate-Risk Prostate Cancer: An Ancillary Study of NRG/RTOG 0815

  Speaker: Angela Jia, MD, PhD - University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland
• 04:05pm - 04:15pm ET

  Digital Pathology-Based Multimodal Artificial Intelligence Biomarker Validation In Patients with High and Very High Risk Localized Prostate Cancer from the POP-RT Trial

  Speaker: Vedang Murthy, MD - Tata Memorial Centre, New Mumbai
• 04:15pm - 04:25pm ET

  Multi-institutional Transcriptomic Characterization of Radiorecurrent Prostate Cancer and Prognostic Biomarkers after Salvage Re-Irradiation in the F-SHARP Clinical Trial

  Speaker: Abhishek Solanki, MD, MS - Loyola University Medical Center, Maywood
• 04:25pm - 04:35pm ET

  Long-Term Transcriptomic Analysis of NRG/RTOG 9601: A Phase 3 Study of Salvage Radiotherapy for Prostate Cancer with or without Anti-Androgen Therapy

  Speaker: Krishnan Patel, MD - The University of Texas MD Anderson Cancer Center, Houston
• 04:35pm - 04:45pm ET

  Interpreting the Model: Biologic Pathways Underlying a Clinically Validated Multimodal Digital Pathology AI Biomarker in Metastatic Prostate Cancer

  Speaker: Philip Sutera, MD - University of Rochester Medical Center, Rochester
• 04:45pm - 04:55pm ET

  Discussant

  Speaker: David Miyamoto, MD, PhD - Massachusetts General Hospital, Boston